Blue Reliever Reliance Test

0% completed
“Using my Blue Reliever Inhaler to treat symptoms is the best way to keep on top of my asthma.”
20% completed
“I don’t worry about asthma when I have my Blue Reliever Inhaler around.”
40% completed
“My Blue Reliever Inhaler is the only asthma treatment I can really rely on.”
60% completed
“The benefits of using my Blue Reliever Inhaler easily outweigh any risks.”
80% completed
“I prefer to rely on my Blue Reliever Inhaler rather than my Steroid Preventer Inhaler.”
90% completed
What is your age?
99% completed
Are you…
This is a self-test designed to help you and your doctor, nurse or pharmacist to understand what you think about your Blue Reliever Inhaler* for asthma and whether you might be relying on it too much.
The Reliever Reliance Test is adapted from the validated and globally used Beliefs about Medicines Questionnaire(4) and has been developed by leading expert in behavioural medicine, Professor Rob Horne, with colleagues from the International Primary Care Respiratory Group (IPCRG). It was fully funded by AstraZeneca UK Limited. The Asthma Right Care initiative is a global movement led by the IPCRG funded by Astrazenca globally.
This is not medical advice. DO NOT stop or change your asthma medication without consulting your health care professional.

• NICE Guideline [NG80]. Asthma: diagnosis, monitoring and chronic asthma management. November 2017. • Global Initiative for Asthma (GINA). Pocket Guide for asthma management and prevention (for adults and children older than 5 years). 2019. Available from: www.ginasthma.org [last accessed 08.05.19]. • Price D, Fletcher M, van der Molen T. NPJ Prim Care Respir Med. 2014; 24:14009. • Partridge MR, van der Molen T, Myrseth SE, et al. BMC Pulm Med. 2006; 6:13. • Horne R, Weinman J, Hankins M. Psychology & Health. 1999; 14(1):1-24. © Prof Rob Horne

Global Initiative for Asthma - Global Initiative for Asthma – GINA We work with health care professionals and public health officials around the globe to reduce asthma prevalence, morbidity, and mortality. www.ginasthma.org

Developed by leading expert in behavioral medicine, Professor Rob Horne, University College London (UCL), with colleagues from the International Primary Care Respiratory Group (IPCRG), and fully funded by AstraZeneca UK Limited.

Disclaimer

The information contained on this website does not represent medical recommendations. If in doubt, consult a doctor.
The notes contained in this website page exclusively represent the opinion of the authors of the articles in reference and not that of AstraZeneca or the Medical Associations and Societies involved in Asthma.
This is not a platform to promote any product or Health Care Professional (HCP). This is only for patient and HCP education on Asthma and its complications.

For Gulf:

AstraZeneca International | Gulf
17th Floor, South Tower,
Dubai Science Park,
PO Box 505070, Dubai – UAE
T: +971 4 3624888
F: +971 4 3624889

​For Medical Information Enquiries:

Website: https://contactazmedical.astrazeneca.com
Email: gulf-medicalinfo@astrazeneca.com

​For Reporting Adverse events and/or Product Quality Complaints:

Website: https://contactazmedical.astrazeneca.com
Email: Patientsafety-azgulf@astrazeneca.com

Approval code Z5-4438

Legal notice and terms of usePrivacy noticeCookie policyContact Us